Theriva Biologics, Inc. (TOVX)
USD 1.04
(-0.95%)
USD 1.04
(-0.95%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 162 Thousand USD | -88.49% |
| 2022 | 1.4 Million USD | 0.36% |
| 2021 | 1.4 Million USD | 654.3% |
| 2020 | 186 Thousand USD | -60.68% |
| 2019 | 473 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 12.78 Thousand USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2002 | 10.5 Million USD | 110.0% |
| 2001 | 5 Million USD | 150.0% |
| 2000 | 2 Million USD | 0.0% |
| 1999 | 2 Million USD | 100.0% |
| 1998 | 1 Million USD | -37.5% |
| 1997 | 1.6 Million USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 93 Thousand USD | -41.51% |
| 2024 Q1 | 159 Thousand USD | -1.85% |
| 2023 Q4 | 162 Thousand USD | -90.45% |
| 2023 Q2 | 1.83 Million USD | -6.37% |
| 2023 Q3 | 1.69 Million USD | -7.68% |
| 2023 FY | 162 Thousand USD | -88.49% |
| 2023 Q1 | 1.96 Million USD | 39.35% |
| 2022 FY | 1.4 Million USD | 0.36% |
| 2022 Q1 | 1.58 Million USD | 12.62% |
| 2022 Q2 | 1.51 Million USD | -4.18% |
| 2022 Q3 | 1.44 Million USD | -4.49% |
| 2022 Q4 | 1.4 Million USD | -2.63% |
| 2021 Q4 | 1.4 Million USD | 0.14% |
| 2021 Q1 | 108 Thousand USD | -41.94% |
| 2021 Q2 | 1.42 Million USD | 1220.37% |
| 2021 FY | 1.4 Million USD | 654.3% |
| 2021 Q3 | 1.4 Million USD | -1.75% |
| 2020 Q1 | 405 Thousand USD | -14.38% |
| 2020 Q4 | 186 Thousand USD | -28.74% |
| 2020 Q3 | 261 Thousand USD | -21.86% |
| 2020 Q2 | 334 Thousand USD | -17.53% |
| 2020 FY | 186 Thousand USD | -60.68% |
| 2019 Q3 | 539 Thousand USD | -10.32% |
| 2019 FY | 473 Thousand USD | 0.0% |
| 2019 Q4 | 473 Thousand USD | -12.24% |
| 2019 Q2 | 601 Thousand USD | -9.21% |
| 2019 Q1 | 662 Thousand USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q3 | 1910.00 USD | -55.43% |
| 2010 Q4 | - USD | -100.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q1 | 9201.00 USD | -28.05% |
| 2010 Q2 | 4285.00 USD | -53.43% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 12.78 Thousand USD | 0.0% |
| 2009 Q4 | 12.78 Thousand USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | 600 Thousand USD | 71.43% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q2 | 350 Thousand USD | -12.5% |
| 2007 Q1 | 400 Thousand USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2003 Q1 | 10.5 Million USD | 0.0% |
| 2002 Q3 | 11.5 Million USD | 0.0% |
| 2002 Q2 | 11.5 Million USD | 15.0% |
| 2002 FY | 10.5 Million USD | 110.0% |
| 2002 Q1 | 10 Million USD | 100.0% |
| 2002 Q4 | 10.5 Million USD | -8.7% |
| 2001 Q4 | 5 Million USD | 66.67% |
| 2001 Q3 | 3 Million USD | 50.0% |
| 2001 Q1 | 2 Million USD | 0.0% |
| 2001 FY | 5 Million USD | 150.0% |
| 2001 Q2 | 2 Million USD | 0.0% |
| 2000 Q4 | 2 Million USD | 0.0% |
| 2000 FY | 2 Million USD | 0.0% |
| 2000 Q3 | 2 Million USD | 0.0% |
| 2000 Q1 | 2 Million USD | 0.0% |
| 2000 Q2 | 2 Million USD | 0.0% |
| 1999 FY | 2 Million USD | 100.0% |
| 1999 Q1 | 1.5 Million USD | 50.0% |
| 1999 Q2 | 1.5 Million USD | 0.0% |
| 1999 Q3 | - USD | -100.0% |
| 1999 Q4 | 2 Million USD | 0.0% |
| 1998 FY | 1 Million USD | -37.5% |
| 1998 Q1 | 900 Thousand USD | -43.75% |
| 1998 Q4 | 1 Million USD | 100.0% |
| 1998 Q3 | 500 Thousand USD | 0.0% |
| 1998 Q2 | - USD | -100.0% |
| 1997 FY | 1.6 Million USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | 1.8 Million USD | 0.0% |
| 1997 Q4 | 1.6 Million USD | -11.11% |
| 1997 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | 67.273% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 82.3 Million USD | 99.803% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | 89.695% |
| Azitra, Inc. | 563.69 Thousand USD | 71.261% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -1146.154% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | 92.136% |
| CEL-SCI Corporation | 11.6 Million USD | 98.604% |
| iBio, Inc. | 3.5 Million USD | 95.381% |
| Lineage Cell Therapeutics, Inc. | 2.07 Million USD | 92.174% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 94.404% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 91.345% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | 85.379% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | 97.001% |
| BiomX Inc. | 5.4 Million USD | 97.001% |
| Protalix BioTherapeutics, Inc. | 4.62 Million USD | 96.494% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | 1.088% |
| Scorpius Holdings, Inc. | 12.61 Million USD | 98.716% |